![](https://www.diabetesnews.com/wp-content/uploads/2014/02/FDA-Logo-150x150.jpg)
Lilly just announced that the FDA has approved its Humalog 200 units/mL KwikPen (insulin lispro) for type 1 and type 2 diabetes, making it the first concentrated mealtime insulin analog to reach the US market.
Lilly just announced that the FDA has approved its Humalog 200 units/mL KwikPen (insulin lispro) for type 1 and type 2 diabetes, making it the first concentrated mealtime insulin analog to reach the US market.